Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Launched on June 12, 2000, the iShares U.S. Healthcare ETF (IYH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.

Zacks Investment Research • Oct 26, 2026

Vanguard Health Care ETF vs iShares U.S. Healthcare ETF

Vanguard Health Care ETF provides significantly broader exposure with 411 holdings compared to 100 for iShares U.S. Healthcare ETF. The Vanguard fund maintains a lower expense ratio of 0.09%, while the iShares fund charges 0.37%.

The Motley Fool • Oct 21, 2026

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

The iShares U.S. Healthcare ETF offers a lower expense ratio and a higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides concentrated exposure to over 200 biotech companies, while the iShares U.S. Healthcare ETF holds 100 diverse healthcare positions.

The Motley Fool • Oct 11, 2026

IYH Beats IXJ on Returns While Global Fund Offers Higher Yield

iShares Global Healthcare ETF provides broad exposure to international medical companies with a higher dividend yield than its domestic counterpart. iShares U.S. Healthcare ETF concentrates on American companies and has produced higher total returns over the past year and five-year periods.

The Motley Fool • Oct 6, 2026

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF carries a lower expense ratio and delivered higher total returns over the trailing 12 months than the iShares U.S. Healthcare ETF. The iShares U.S. Healthcare ETF provides broader industry diversification across the medical sector, while the Invesco Nasdaq Biotechnology ETF focuses strictly on biotechnology and pharmaceuticals.

The Motley Fool • Sep 23, 2026

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • Sep 18, 2026

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.

The Motley Fool • Sep 9, 2026

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Seeking Alpha • Sep 8, 2026

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street's growing shift toward healthcare amid continued geopolitical tensions in the Middle East.

Seeking Alpha • Aug 31, 2026

PPH vs. IYH: Which Healthcare Fund Is the Better Buy?

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure across the healthcare sector, whereas the VanEck Pharmaceutical ETF (NYSEMKT:PPH) concentrates specifically on pharmaceutical stocks. PPH offers a slightly lower expense ratio and a higher dividend yield than IYH.

The Motley Fool • Aug 18, 2026